Gilead Submits Application To FDA Asking For PrEP Approval For Truvada

Gilead Submits Application To FDA Asking For PrEP Approval For Truvada

Friday, December 16, 2011

Pharmaceutical company Gilead Sciences on Thursday submitted an application to the FDA asking the agency to approve its antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection�among adults, a�Gilead press release reports. "If the [application] is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV through sex," the press release notes (12/15).

Several international studies of the drug have shown it can reduce the risk of HIV infection among adults, according to the San Jose Mercury News. "It remains uncertain how the FDA will respond to the request, and reviews of drug applications can take years," the newspaper writes (Johnson, 12/15). The press release notes that "CDC is currently developing formal U.S. Public Health Service guidelines for the use of PrEP" (12/15).

The Kaiser Daily Global Health Policy Report is published by the Kaiser Family Foundation. 2011 Henry J. Kaiser Family Foundation. All rights reserved. The report summarizes the latest, most relevant information on U.S. global health policy developments and related news from hundreds of sources. Access today's full report or sign up for an email subscription to the Daily Report.

Source: http://feeds.kff.org/~r/kff/kdghpr/~3/8WJVFoD5yNI/GH-121611-Gilead-Truvada.aspx

exercise ball exercises for a flat stomach exercise tv men\\\'s health